ATROVENT NASAL SPRAY 0.03% Rx
Generic Name and Formulations:
Ipratropium bromide 0.03% (21mcg/spray); aqueous soln.
Boehringer Ingelheim Pharmaceuticals
Indications for ATROVENT NASAL SPRAY 0.03%:
Rhinorrhea associated with allergic and nonallergic perennial rhinitis.
Adults and Children:
<6yrs: not recommended. ≥6yrs: 2 sprays in each nostril 2–3 times daily.
Allergy to atropine or its derivatives.
Avoid eyes. Narrow-angle glaucoma. GI or GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Epistaxis, pharyngitis, nasal dryness or irritation, other nasal symptoms, nausea.
Nasal spray—30mL (345 sprays)
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis